Role of biosimilars in neutropenia prevention in cancer patients

Role of biosimilars in neutropenia prevention in cancer patients

Show other versions (1)

Bibliographic Details
Main Author:	V. V. Ptushkin
Format:	Article
Language:	Russian
Published:	ABV-press 2015-01-01
Series:	Онкогематология
Subjects:	chemotherapy neutropenia granulocyte colony stimulating factor biosimilars zarsio
Online Access:	https://oncohematology.abvpress.ru/ongm/article/view/122

Similar Items

Role of biosimilars in neutropenia prevention in cancer patients
by: V. V. Ptushkin
Published: (2015-01-01)

Modern concepts of biosimilars in hematology and oncology
by: V. V. Ptushkin
Published: (2014-07-01)

Modern concepts of biosimilars in hematology and oncology
by: V. V. Ptushkin
Published: (2014-07-01)

Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar
by: Schwartzberg LS, et al.
Published: (2018-09-01)

The frequency of regimens associated with high risk of febrile neutropenia and the incidence of dose-limiting neutropenia among patients receiving cytotoxic therapy for malignancies: the FLAME study results
by: Anton V. Snegovoy, et al.
Published: (2023-12-01)

Prevention of neutropenia during chemotherapy by prolonged myelostimulatory preparations
by: V. V. Ptushkin, et al.
Published: (2015-06-01)

Prevention of neutropenia during chemotherapy by prolonged myelostimulatory preparations
by: V. V. Ptushkin, et al.
Published: (2015-06-01)

Budget Saving Potential of Pegfilgrastim Biosimilar for the Treatment of Chemotherapy-Induced Febrile Neutropenia, in Italy
by: Patrizia Berto, et al.
Published: (2022-02-01)

Chemotherapy limiting neutropenia. Is prevention required?
by: I. B. Kononenko, et al.
Published: (2022-01-01)

Clinical manifestations and outcomes of pediatric chronic neutropenia
by: Chuan Wan, et al.
Published: (2012-04-01)

Lipegfilgrastim in patients with chemotherapy-induced neutropenia
by: G. D. Petrova, et al.
Published: (2015-12-01)

Biosimilars in the management of neutropenia: focus on filgrastim
by: Caselli D, et al.
Published: (2016-02-01)

Neutropenia in pediatric hematology/oncology practice
by: E. A. Deordieva, et al.
Published: (2015-06-01)

Neutropenia in pediatric hematology/oncology practice
by: E. A. Deordieva, et al.
Published: (2015-06-01)

Simultaneous treatment with carbimazole and granulocyte-colony stimulating factor in a patient with thyrotoxicosis and carbimazole induced neutropenia
by: Talapatra Indrajit, et al.
Published: (2006-12-01)

Efficacy and Safety of Filgrastim and Its Biosimilars to Prevent Febrile Neutropenia in Cancer Patients: A Prospective Study and Meta-Analysis
by: Shruti Rastogi, et al.
Published: (2021-10-01)

Experience in prevention of neutropenia in patients with disseminated soft tissue sarcomas receiving polychemotherapy
by: L Yu Vladimirova, et al.
Published: (2016-09-01)

Pegfilgrastim on febrile neutropenia in pediatric and adolescent cancer patients: a systematic review and meta-analysis
by: Xia Zhu, et al.
Published: (2023-12-01)

Real-World Incidence of Febrile Neutropenia among Patients Treated with Single-Agent Amrubicin: Necessity of the Primary Prophylactic Administration of Granulocyte Colony-Stimulating Factor
by: Yosuke Dotsu, et al.
Published: (2021-09-01)

Improved risk prediction of chemotherapy‐induced neutropenia—model development and validation with real‐world data
by: Mikko S. Venäläinen, et al.
Published: (2022-02-01)

Safety and tolerability of Peg-grafeel™, a pegfilgrastim, for the prophylactic treatment of chemotherapy-induced neutropenia and febrile neutropenia: A prospective, observational, postmarketing surveillance study in India
by: Vineet Talwar, et al.
Published: (2017-01-01)

Severe congenital neutropenia mimicking chronic idiopathic neutropenia: a case report
by: Juhyung Kim, et al.
Published: (2023-07-01)

Clinical Outcomes of Secondary Prophylactic Granulocyte Colony-Stimulating Factors in Breast Cancer Patients at a Risk of Neutropenia with Doxorubicin and Cyclophosphamide-Based Chemotherapy
by: Jae Hee Choi, et al.
Published: (2021-11-01)

Current management of chemotherapy-induced neutropenia in adults: key points and new challenges
by: Yi Ba, et al.
Published: (2020-11-01)

The Prognostic Utility of Lymphocyte-Based Measures and Ratios in Chemotherapy-Induced Febrile Neutropenia Patients following Granulocyte Colony-Stimulating Factor Therapy
by: Omar M. Halalsheh, et al.
Published: (2022-10-01)

Comparison of Efficacy and Safety of Lupin’s Pegfilgrastim with Neulastim® as an Adjunct to Chemotherapy in Patients with Non Myeloid Malignancies: A Randomised Phase III Clinical Study
by: Minish Jain, et al.
Published: (2022-08-01)

Granulocyte colony-stimulating factor usage in drug-induced neutropenia after kidney transplantation: a single-center experience
by: Emel Isiktas Sayilar, et al.
Published: (2020-01-01)

Biosimilar filgrastim treatment patterns and prevention of febrile neutropenia: a prospective multicentre study in France in patients with solid tumours (the ZOHé study)
by: Henri Roché, et al.
Published: (2018-11-01)

Chronic Refractory Uveitis in a Patient with Childhood-Onset Cyclic Neutropenia
by: Li-Li Chen, et al.
Published: (2011-05-01)

Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective study
by: Yusuke Kitagawa, et al.
Published: (2020-04-01)

Evaluating the Prognostic Role of Monocytopenia in Chemotherapy-Induced Febrile Neutropenia Patients Treated with Granulocyte Colony-Stimulating Factor
by: Alshari O, et al.
Published: (2021-09-01)

Recombinant Ganoderma lucidum Immunomodulatory Protein Improves the Treatment for Chemotherapy-Induced Neutropenia
by: Xinhua Lei, et al.
Published: (2020-06-01)

Efficacy and safety of pegfilgrastim biosimilar MD‐110 in patients with breast cancer receiving chemotherapy: Single‐arm phase III
by: Toshimi Takano, et al.
Published: (2023-10-01)

Clinical confirmation to demonstrate similarity for a biosimilar pegfilgrastim: a 3-way randomized equivalence study for a proposed biosimilar pegfilgrastim versus US-licensed and EU-approved reference products in breast cancer patients receiving myelosuppressive chemotherapy
by: Kalpna Desai, et al.
Published: (2018-09-01)

Efficacy of recombinant human granulocyte colony stimulating factor in very-low-birth-weight infants with early neutropenia
by: Ru-Jeng Teng, et al.
Published: (2015-02-01)

A multicenter phase II trial of primary prophylactic PEG‐rhG‐CSF in pediatric patients with solid tumors and non‐Hodgkin lymphoma after chemotherapy: An interim analysis
by: Junting Huang, et al.
Published: (2023-07-01)

Febrile neutropenia incidence and the variable toxicity profile between brand and generic docetaxel in the adjuvant treatment of breast cancer with docetaxel and cyclophosphamide regimen
by: Flávia Viécili Tarcha, et al.
Published: (2023-12-01)

The importance of the prevention of treatment induced neutropenia in patients with malignant neoplasms of the head and neck
by: Editorial Board
Published: (2021-08-01)

Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy
by: Zsuzsanna Kahan, et al.
Published: (2019-02-01)

Use and effectiveness of pegfilgrastim prophylaxis in US clinical practice:a retrospective observational study
by: Derek Weycker, et al.
Published: (2019-08-01)